Stomach and gut

In the T2D registrational trial, CagriSema roughly doubled gastrointestinal adverse events versus placebo (72.5% vs 34.4%), mostly transient.

GI AEs much more frequent than placebo, mainly transient and mild-to-moderate; GI-specific discontinuation modest.

Across the roster, GI AEs cluster during dose escalation and are partially mitigated by slower/lower-starting-dose titration; explicit titration-mitigation evidence...

GLP-1 RAs added to insulin in T1D roughly tripled nausea and vomiting and doubled early treatment withdrawal - a substantial early gastrointestinal burden that eases...

FOLK-CLAIM VERDICTS (GI cluster): (1) 'Nausea is near-inevitable' = OVERSTATED - real and the top AE but ~25-44% (not inevitable), mostly mild-moderate, concentrated...

REAL-WORLD ONLINE SELF-REPORT context for the GI/other folk frequencies. This is a SIGNAL-DETECTION / pharmacovigilance-adjacent dataset, NOT prevalence, NOT...

FOLK-CLAIM VERDICT ('sulfur burps' / rotten-egg belches): UNPROVEN - this is the clearest GENUINE EVIDENCE GAP in the GI cluster. The phenomenon is a widespread,...

Across the AWARD programme, dulaglutide's most common adverse events are gastrointestinal (nausea, diarrhoea, vomiting), dose-related and mostly mild-to-moderate and...

In the AWARD-6 head-to-head, study or study-drug discontinuation because of adverse events was the same for once-weekly dulaglutide and once-daily liraglutide.

GI AEs more frequent than placebo, largely mild-to-moderate, transient, in escalation; AE-related discontinuation higher than placebo.

In a weight-maintenance setting (after injectable tirzepatide or semaglutide), most common AEs with orforglipron were GI, mostly mild-to-moderate.

GI AEs most common, mostly mild-to-moderate, concentrated in escalation; per-symptom rates and AE-related discontinuation dose-related.

Review-channel: safety profile consistent with GLP-1 class, dominated by manageable GI events mitigated by slow escalation; small mild-pancreatitis signal noted...

GI AEs most common, dose-related, mostly mild-to-moderate; partially mitigated by a lower 2 mg (vs 4 mg) starting dose. Nausea showed a clear dose gradient.

GI effects (esp. nausea, vomiting) most frequent AEs across the PIONEER programme; mild-to-moderate, faded with time. PIONEER 1 trial-product discontinuations...

Nausea and diarrhoea most common AEs; transient, mild-to-moderate. More semaglutide than placebo participants discontinued for GI events.

GI AEs (nausea, diarrhoea, vomiting) markedly more frequent than placebo; dose-dependent, titration-managed; high AE-related discontinuation, mainly GI.

GI AEs most common, mostly mild-to-moderate, primarily during dose escalation; AE-related discontinuation dose-related. Per-symptom rates broadly dose-related (nausea...

SURMOUNT-5 head-to-head: GI AEs most common with both; GI-AE-driven discontinuation occurred more often with semaglutide than tirzepatide.

GI events generally mild-to-moderate and decreased over time; treatment-related discontinuations modest.

Predominantly GI TEAEs, mild-to-moderate, dose-dependent; all resolved

GI disorders and injection-site reactions most frequent; more than placebo

GI adverse events (nausea, vomiting) most common; decreased over time

Generally well tolerated; GI adverse events mostly mild-to-moderate, consistent with incretin class.

High GI adverse-event burden, dose-related, driving high discontinuation.

Most adverse events mild-to-moderate GI; few discontinuations.

Slightly higher AEs vs semaglutide, mainly GI

Well tolerated with infrequent gastrointestinal adverse events.

Gastrointestinal adverse events common but mitigated by lower starting dose and dose escalation.

Mild-to-moderate GI TEAEs; no serious AEs in phase 1b

Predominantly mild-to-moderate GI adverse events, mostly during dose escalation; higher AE-related discontinuation than placebo/active comparators.

Well tolerated in MASLD study with no severe/serious AEs

Reported safe and well tolerated at all dose levels (company)

Nausea most common AE; slows gastric emptying

GI events dominant; higher than placebo

AE-related discontinuation in phase 2 higher than the favourable phase 1 profile suggested.